IntegriChain delivers the life science industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, managed services and expert advisors to power their operations and harness the value of their channel, patient and payer data.
View all products
From the first launch to ongoing market access execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We are the data and application backbone for market access departments of Life Sciences manufacturers, enabling them to accelerate their commercialization process, digitalize their operations, and get therapies to patients faster.
Solutions overview
To ensure you get the most out of your access and commercialization investment, IntegriChain provides a complete set of professional Advisory and Systems Integration Services designed to further your business and success.
Services overview
IntegriChain provides wide array of resources to help you navigate your journey to market access success.
Resources overview
We help all stakeholders in the life sciences industry drive access. We do this through our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts and pricing, gross-to-net, channel, and patient services – unlocking strategic payer, provider, pharmacy and patient access insights for our life sciences customers.
Learn more about our company
Keep in touch with IntegrChain through our news and frequent events.
View all news & events
Our Data Science and Innovation teams employ a variety of leading-edge AI/ML methodologies to deliver insights that help save patient days of therapy. The teams utilize a number of AI/ML models – including Random Forest Classification, XGBoost Classification, Kalman Filter, K-Nearest Neighbor, K-Means Clustering, and ARIMA Modeling.
Below are just some of the innovations we’ve developed.
We use a variety of data sets to predict the likelihood that patients who are referred for Specialty medication will not be able to initiate on therapy due to patient journey roadblocks such as their insurance company denying coverage.
We use a variety of data sets to predict the likelihood that patients who are already on therapy for Specialty medication will discontinue therapy before their next refill.
We employ disparate data sets to project future inventory demand for each channel and National Drug Code (NDC) combination.
We produce statistically significant lists of pharmacies for the Pharmacy Call Programs that allow for intelligent, focused, and efficient outreach to pharmacies, maximizing the investments in these programs.
We employee NDC and brand-level features–such as channel level sales distribution, therapeutic category, and WAC price–to determine similar NDCs/brands for various analytic projects.
Like innovation? Consider joining us.Check Out Our Career Openings
